Showing results (561-570 of 586) with videos related to
Sort By:
Pageof 59
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2026
The pan-tumor landscape of gene amplifications and copy number amplification ratio for established and emerging clinical targetsJessica K Lee, Julia C F Quintanilha, Kuei-Ting Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2020
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid TumorsTimothy A Yap, Brent O'Carrigan, Marina S Penney, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2014
Antitumor activity in RAS-driven tumors by blocking AKT and MEKAnthony W Tolcher, Khurum Khan, Michael Ong, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b ResultsEzra Y Rosen, Timothy A Yap, Elisa Fontana, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2023
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)Funda Meric-Bernstam, James M Ford, Peter J O'Dwyer, et al.Nature Medicine|June 5, 2023
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial resultsTimothy A Yap, Elisa Fontana, Elizabeth K Lee, et al.Iscience|February 24, 2023
Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancerDeanna Glassman, Mark S Kim, Meredith Spradlin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2021
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid MalignanciesAparna Hegde, Priyamvada Jayaprakash, Coline A Couillault, et al.Cancer Discovery|March 26, 2026
Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid TumorsBurak Uzunparmak, Fei Su, Amber Johnson, et al.Cancer Research|July 17, 2026
Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor ResistanceKaixin Cheng, Hao Nie, Wei Zhou, et al.Pageof 59